ArticleScientific reports2025
Dose dependent toxicity of streptozotocin inducing diabetic complications in male Sprague Dawley rats with metabolic biochemical histopathological effects.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation the role of quinoa seeds in attenuation the brain cellular senescence and aging induced by D-galactose and γ-radiation in rats: insights into autophagy, telomerase activity, amyloid-β and tau proteins.Inflammopharmacology · 2026Article
- Alpha‑lipoic acid-loaded chitosan nanoparticles ameliorate streptozotocin‑induced diabetic liver injury via Nrf2/HO‑1 activation and TLR4/NF‑κB and JAK2/STAT1 inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, leading to microvascular and macrovascular complications including cardiomyopathy, retinopathy, neuropathy, and nephropathy. This study evaluated the diabetogenic potential and pathological outcomes of two single intraperitoneal doses of streptozotocin (STZ) in male Sprague Dawley rats. Twenty-four rats (200-220 g) were randomly assigned to three groups (n = 8/group): control, STZ 45 mg/kg, and STZ 60 mg/kg. DM was confirmed 72 h post-injection via elevated serum glucose. At the end of the experiment, blood and tissue samples were collected to assess metabolic parameters, lipid profile, liver function, oxidative stress markers, inflammatory cytokines, and histopathological changes. Both doses induced significant hyperglycemia, elevated glycated hemoglobin, and reduced insulin levels. Diabetic rats also showed dyslipidemia, liver dysfunction, increased oxidative stress (↓GSH, ↑MDA), and elevated inflammatory markers (TNF-α, il-6). Histopathological and morphometric analyses confirmed tissue damage and biochemical alterations. Notably, the 60 mg/kg dose produced a more severe and consistent diabetic phenotype, with greater metabolic derangements, oxidative injury, inflammation, and organ pathology compared to the 45 mg/kg dose. These findings suggest that while both doses effectively induce experimental diabetes, 60 mg/kg STZ provides a more robust model for studying DM-associated complications in vital organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.